3rd CEE Meeting on Viral Hepatitis and Co-infection with HIV – Presentations

  Session 1: Epidemiology / access to treatment
Chair: Jonathan Schapiro
 Maticic, Mojca 2015_120Local situation in in Slovenia and Balkan Countries (not yet available)
Mojca Maticic, MD, PhDUniversity Medical Centre Ljubljana, Slovenia
 Golubovska, Olga 2017Local situation in Ukraine
Olga Golubovska, MD - Bogomolets National medical University, Ukraine
 Rassokhin, Vadim 2015_120Local situation in Russia
Vadim Rassokhin, MD  - First St. Petersburg State Medical University named Acad IP Pavlov, Russia
 Sandulescu, Oana_ 2016websiteLocal situation in Romania
Oana Sandulescu, MD, PhD - Carol Davila University of Medicine and Pharmacy, Romania
 Caplinskas, Saulius 2015_120Local situation in Baltic Countries
Saulius Caplinskas, MD, PhD - Lithuanian Centre for Communicable Diseases and AIDS, Lithuania
 Abutidze Akaki, 2016Local situation in Georgia
Akaki Abutidze, MD, MPH - AIDS and Clinical Immunology Research Centre, Georgia
 Aster, Viktor 2015_120Local situation in Czech and Slovak Republics
Viktor Aster, MD, PhD - Charles University, Czech Republic
 Horban, Andzej 2014_120Local situation in Poland
Andrzej Horban, MD, PhD - University of Warsaw, Poland
 Hunyady, Bela 2017Local situation in Hungary (not yet available)
Béla Hunyady, MD - Somogy County Kaposi Mór Teaching Hospital, Hungary
 Lazarus, Jeoffrey 2014_headshot_120x160Hep-CORE study: management of HBV and HCV infections throughout Europe
Jeffrey Lazarus, PhD - Copenhagen University Hospital, Denmark
 Poljak, Mario 2017 120x160New testing strategies for HCV: how can we achieve the WHO targets? (temporarily unavailable)
Mario Poljak, MD, PhD - University of Ljubljana, Slovenia
 Round table discussion: access to HepC treatment

Presentations:
Introduction to Access to hepC treatment in EECA
Key barriers to hepC treatment for PWIDs
Direct price negotiations
Compulsory licensing and patent opposition
MPP progress in VL

  Session 2: Challenges in the management of HCV infected patients
Chairs: Jürgen Rockstroh and Milosz Parczewski
 Peck-Radosavljevic, Markus 2017Management of HCC in HCV -infected patients
Markus Peck-Radosavljevic, MD - Klinikum Klagenfurt am Wörthersee, Austria
 Khaykin, Pavel 2014_120Clinical case: re-treatment of HCV DAA failure with 3-class resistance
Pavel Khaykin, MD - MainFachArzt, Germany
 
 Session 3: Epidemiology, clinical presentation and management of Hepatitis E virus
 Wedemeyer, Heiner 2014_120-160Management of Hepatitis E virus
Heiner Wedemeyer, MD - Medical School Hannover, Germany

Thursday 28 September - Day 2

  
 Session 4: Treatment challenges in HIV & HCV – special populations
 Parczewski, Milosz 2015_120Special challenges in curbing the HIV epidemic in Central/Eastern Europe
Miłosz Parczewski, MD, PhD - Pomeranian Medical University, Szczecin, Poland
 Results of Hepatitis C virus (hcv) treatment program among people with hiv/hcv co-infection who inject drugs (PWID)
Mr. Sergii Filipovich
 
 HIV infection outbreak among IDUs in Minsk
Prof. Vladimir Eremin
 
 Session 5: Abstract - driven presentations
 Real-world effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program

Prof. Tengiz Tsertsvadze

#2
 Clinical characteristics of patients seeking care for chronic HCV infection – results from the large observational study in Central and Eastern European region and Kazakhstan (MOSAIC Study) (to be published later)

Dr. Béla Hunyady
#3
 Changes in demographic, epidemiological and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010

Dr. Nina Kmet Lunarcek
#4
 Prognostic factors for liver fibrosis regression following sustained virologic response in patients with hepatitis C treated with direct acting antivirals

Dr. Oana Sandulescu
#5
 Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia

Dr. Ligita Jancoriene
#6
 Special session: Future directions of ARVs
 Boucher, Charles 2017Virologist Perspective
Charles Boucher, MD, PhD - Erasmus University, the Netherlands
 Clinician Perspective (not yet available)
Jonathan Schapiro, MD - Sheba Medical Centre, Israel
 Khoo, Saye 2012Pharmacologist Perspective
Saye Khoo, MD, PhD - University of Liverpool, United Kingdom
 Session 6 Future in Diagnostic & Therapeutic Approaches
 Otelea, Dan 2017 120x160Innovative diagnostics for HIV, HBV and HCV
Dan Otelea, MD, PhD - Nat. Institute for Inf. Diseases “Prof. Dr. Matei Bals”, Romania
 Van Damme, Pierre 2017The challenges in hepatitis B vaccination (not yet available)
Pierre Van Damme, MD, PhD - University of Antwerpen, Belgium